The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors

Pharmaceutical Research

Volumn 17, Issue 5, 2000, Pages 505-514

  Minko, Tamara ^a   Kopečkova, Pavla ^a,b   Pozharov, Vitaliy ^c   Jensen, Keith D ^a   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b University of Utah   (United States)

^c Olympus Research   (United States)

Author keywords

Antitumor activity; Doxorubicin; Enhanced permeability and retention effect; HPMA copolymer; Necrosis; VEGF gene

Indexed keywords

DNA FRAGMENT; DOXORUBICIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RETENTION; GENE EXPRESSION; HUMAN; HUMAN CELL; MACROMOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAPILLARY PERMEABILITY; DOXORUBICIN; DRUG CARRIERS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MACROMOLECULAR SUBSTANCES; METHACRYLATES; MICE; NECROSIS; OVARIAN NEOPLASMS; PERMEABILITY; REGIONAL BLOOD FLOW; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034046024     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007500412442     Document Type: Article

References (30)

1. 1. T. Minko, P. Kopečková, V. Pozharov, and J. Kopeček. HPMA copolymer bound adriamycin overcomes MDRI gene encoded resistance in a human ovarian carcinoma cell line. J. Contr. Rel. 54:223-233 (1998).
2. 2. T. Minko, P. Kopečková, and J. Kopeček. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Contr. Rel. 59:133-148 (1999).
3. 3. T. Minko, P. Kopečková, and J. Kopeček. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma calls. Pharm. Res. 16:986-996 (1999).
4. 4. T. Minko, P. Kopečková, and J. Kopeček. Efficacy of the chemotherapeutic action of HPMA coppolymer bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer, 86:108-117 (2000).
5. 5. Y. Matsumura and H. Maeda. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46:6387-6392 (1986).
6. 6. H. Maeda, L. M. Seymour, and Y. Miyamoto. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:351-362 (1992).
7. 7. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, and H. Maeda. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89:307-314 (1998).
8. 8. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytry̌, J. B. Lloyd, and R. Duncan. Synthetic polymeric drugs. U.S. Pat. 5,037,883 (Aug. 6, 1991).
9. 9. V. G. Omelyanenko, P. Kopečová, C. Gentry, J.-G. Shiah, and J. Kopeček. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the methods of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Target. 3:357-373 (1996).
10. 10. V. Omelyanenko, P. Kopečková, C. Gentry, and J. Kopeček. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Contr. Rel. 53:25-37 (1998).
11. 11. E. Tischler, R. Mitchell, T. Hartman, M. Silva, D. Gospodarowicz, J. C. Fiddes, and J. A. Abraham. The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon aplicing. J. Biol. Chem. 266:11947-11954 (1991).
12. 12. B. C. Trauth, C. Klas, A. M. Peters, S. Matzku, P. Moller, W. Falk, K. M. Debatin, and P. H. Krammer. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:301-305 (1989).
13. 13. H. F. Dvorak, J. A. Nagy, J. T. Dvorak, and A. M. Dvorak. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133:95-109 (1988).
14. 14. F. Yuan, M. Dellian, D. Fukumura, M. Leuning, D. A. Berk, V. P. Torchilin, and R. K. Jain. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55:3752-3756 (1995).
15. 15. L. E. Benjamin, R. Goljanin, A. Irin, D. Pode, and E. Keshet. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:159-165 (1999).
16. 16. S. Mesiano, N. Ferrara, and R. B. Jaffe. Role of vascular endothelial growth factor in ovarian cancer. Am. J. Pathol. 153:1249-1256(1998).
17. 6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J. Contr. Rel. 61:145-157 (1999).
18. 18. Y. Tabata, T. Kawai, Y. Murakami, and Y. Ikada. Electric charge influence of dextran derivatives on their tumor accumulation after intravenous injection. Drug Delivery 4:213-221 (1997).
19. 19. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95:4607-4612 (1998).
20. 20. Y. Murakami, Y. Tabata, and Y. Ikada, Effect of the molecular weight of water-soluble polymers on accumulation at an inflammatory site following intravenous injection. Drug Delivery 3: 231-238 (1996).
21. 21. Z-R. Lu, P. Kopečková, Z. Wu, and J. Kopeček. Synthesis of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] by radical polymerization in the presence of alkyl mercaptans. Macromol. Chem. Phys. 200:2022-2030 (1999).
22. 22. Y. Takakura and M. Hashida. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic consideration on biodistribution. Pharm. Res. 13:820-831 (1996).
23. 23. H. M. Sowter, A. N. Corps, A. L. Evans, D. E. Clark, D. S. Charnok-Jones, and S. K. Smith. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab. Invest. 77:607-614 (1997).
24. 24. N. Ferrara and W. J. Henzel. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:851-858 (1989).
25. 25. N. Ravindranath, L. Little-Ihrig, H. S. Phillips, N. Ferrara, and A. J. Zeleznik. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology131:254-260 (1992).
26. 26. T. A. Oison, D. Mohanraj, L. F. Carson, and S. Ramakrishnan. Vascular permeability gene expression in normal and neoplastic human ovaries. Cancer Rex. 54:276-280 (1994).
27. 27. D. R. Senger, C. A. Perruzzi, J. Feder, and H. F. Dvorak. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46:5629-5632 (1986).
28. 28. B. Berse, L. F. Brown, L. Van De Watter, A. Papadopoulos-Sergiou, C. A. Perruzzi, E. J. Manseau, H. F. Dvorak, and D. R. Senger. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell 3:211-220 (1992).
29. th International Symposium on Recent Advances in Drug Delivery Systems, February 22-25, 1999, Salt Lake City, USA, p. 114-117.
30. 30. J. Lankelma, H. Dekker, R. F. Luque, S. Luykx, K. Hoekman, P. van der Valk, P. J. van Diest, and H. M. Pinedo. Doxorubicin gradients in human breast cancer. Clin. Cancer Res. 5:1703-1707 (1999).